Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban

Mr. Nogueira has been chairman of the committee since the fund’s inception. He joined the Firm in 2004 and has a total of 15 years of investment experience. Since joining the T. Rowe, he has served as a portfolio manager (beginning in 2016) and as an equity research analyst and assisted other portfolio managers in executing certain of the Firm’s equity strategies. Nogueira holds the Chartered Financial Analyst designation.